Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions

Fabian D, Wild C
Record ID 32018005624
Original Title: Health Innovation Next Generation Payment & Pricing Models (HI-PRIX): Balancing Sustainability of Innovation with Sustainability of Health Care
Authors' objectives: New (pharmaceutical) products are becoming increasingly more expensive. As a result of this trend accessibility of pharmaceuticals decreases. However, not all innovation can be attributed to private companies. Subsequently, the role of public institutions such as universities, university spin-offs, and publicly funded biotech start-ups is largely being disregarded during price negotiations. Public funding in the form of research grants, tax incentives, utilisation of clinical infrastructure or regulatory measures make a major contribution. Article 57 of the proposed Pharmaceutical Legislation (PL, Directive) will require market authorisation applicants to publicly declare any direct financial support for R&D received from public authorities. The aim of our research (funded by EU Horizon Europe Grant Agreement Number 101095593) is to increase transparency in (pharmaceutical) R&D to mitigate the risk of market failure associated with information asymmetry by analysing pharmaceutical R&D expenditures for bringing a new medicine to market and which factors influence these expenditures and to identify the categories needed to capture direct or indirect public contributions to R&D. Our findings are intended to provide a framework for standardised reporting of public contributions and to reduce ambiguity in the interpretation of "direct" and "indirect" public contributions.
Project Status: Completed
Year Published: 2024
URL for additional information:
English language abstract: There is no English language summary available
Publication Type: Other
Country: Austria
MeSH Terms
  • Research
  • Fees, Pharmaceutical
  • Drug Development
  • Public Expenditures
  • Orphan Drug Production
  • Drug Costs
  • Health Care Costs
  • R&D
  • innovation research
  • public contributions
  • product development
  • pharmaceuticals
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name:
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.